Avanir Pharmaceuticals Inc  

(Public, NASDAQ:AVNR)   Watch this stock  
Find more results for AVNR
Jan 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 3.02 - 17.05
Open     -
Vol / Avg. 0.00/9.12M
Mkt cap 3.29B
P/E     -
Div/yield     -
EPS -0.31
Shares 193.76M
Beta 0.91
Inst. own 90%
Feb 9, 2015
Avanir Pharmaceuticals Annual Shareholder Meeting (Estimated) Add to calendar
Dec 10, 2014
Q4 2014 Avanir Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -43.15% -43.85%
Operating margin -41.18% -40.97%
EBITD margin - -39.07%
Return on average assets -26.61% -26.33%
Return on average equity -33.29% -34.56%
Employees 484 -
CDP Score - -


20 Enterprise Ste 200
ALISO VIEJO, CA 92656-7104
United States - Map
+1-949-3896700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).